Krsnaa Diagnostics Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹211Cr
- +19.9% YoY
- +22% QoQ
- Net profit
- ₹16Cr
- −20% YoY
- −62.8% QoQ
- Margin
- 27%
- −2 pp YoY
- −6 pp QoQ
Guidance rank: #4 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
4 of 4 strong
The short version
Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19). Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.
From Krsnaa Diagnost.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19).
- Rajasthan PPP Project: Revenue expected to double in coming quarters with a full-year target of INR100-150 crores, and aspirational target of INR200-250 crores (Pages 8-9).
- Retail Business: Currently contributing around 8-9% of sales, anticipated to grow exponentially by the end of the financial year driven by new wellness and illness packages (Pages 15-16, 19).
- New Projects: Expansion with additional PPP projects in pipeline including Himachal Pradesh and scaling up of MRI centers expected to contribute to top-line growth (Pages 15, 12).
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has raised funds via promoter infusion through warrants.
- These funds are intended for capital expenditure related to ongoing projects and certain acquisitions planned by the company. (Page 10)
- The infrastructure-led business model requires front-ended capital expenditure for building laboratories, installing equipment, and staffing teams before volume ramps up.
- Investments have been made in building labs, diagnostic networks, and launching new MRI centers, especially highlighted in Rajasthan and other PPP projects. (Pages 5, 7, 12)
2 more points from Krsnaa Diagnost.'s call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Rajasthan project is fully operational with 31 Mother labs, 62 hub labs, and 1,228 collection centers, offering significant future revenue visibility and scale.
- Radiology expansion includes 17 MRI centers in the pipeline; 8 MRI centers in Maharashtra were inaugurated and operationalized in Q1 FY27.
- Additional PPP projects in the pipeline beyond Rajasthan are expected to materialize and serve as new growth engines.
- Retail business is expanding rapidly, with over 4,000 touchpoints across 7 states, leveraging an asset-light franchise model for growth.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 211 | 176 | +19.9% | 173 | +22% |
| Operating profit (EBITDA) | 57 | 50 | +14% | 57 | 0% |
| Operating margin | 27% | 29% | -2 pp | 33% | -6 pp |
| Profit before tax | 22 | 26 | -15.4% | 54 | -59.3% |
| Net profit (PAT) | 16 | 20 | -20% | 43 | -62.8% |
| EPS (₹) | 4.88 | 6.03 | -19.1% | 13.37 | -63.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q1 FY27 results?
Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19). Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 17.7 with a market cap of ₹1,755 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
The company has raised funds via promoter infusion through warrants.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
